Maintenance therapy with infliximab—an anti-tumor necrosis factor agent—is standard treatment for moderate to severe pediatric inflammatory bowel disease (IBD).
Using data from a subset of 1087 infants from the CHILD cohort, the researchers investigated the effects of breastfeeding on gut microbiota profiles and the risk childhood overweight compared with formula...
The authors of a recent study aimed to compare daily soluble and insoluble fiber intake among children with inflammatory bowel disease and healthy controls.
Adolescents with obesity carry a number of risk factors for cardiovascular disease, which can be mitigated in part by metabolic and bariatric surgery. A recent study is the first to report predictors of...
Consultant360 recently spoke with David Suskind, MD, who presented at Advances in Inflammatory Bowel Diseases 2017, about the importance of diet as a first-line therapy for pediatric patients with Crohn...
Functional abdominal pain cannot be explained by visible or detectable abnormalities. Probiotics, which promote normal gut physiology and reduce functional symptoms, may be beneficial for children with...
Many patients with gastroesophageal reflux disease have persisting symptoms, despite the efficacy of existing treatments. In a recent study, researchers assessed the safety and efficacy of dexlansoprazole...
In a recent study, Laursen and colleagues sought to examine the impact of probiotic administration (both BB-12 and LGG) on child care absence due to illness in Danish infants.
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in June and July, including the first over-the-counter, nonprescription daily oral contraceptive, the first monoclonal...
